Valuation: AnaptysBio, Inc.

Market Cap 1.93B 1.7B 1.57B 1.45B 2.74B 185B 2.8B 18.83B 7.32B 90.64B 7.26B 7.11B 315B P/E 2026 *
-272x
P/E 2027 * 16.9x
Enterprise Value 1.84B 1.62B 1.49B 1.38B 2.61B 176B 2.67B 17.93B 6.97B 86.32B 6.92B 6.77B 300B EV / Sales 2026 *
16.7x
EV / Sales 2027 * 10.7x
Free-Float
94.32%
Yield 2026 *
-
Yield 2027 * -
1 day-2.93%
1 week-3.19%
Current month-3.19%
1 month+29.74%
3 months+5.18%
6 months+44.55%
Current year+34.80%
1 week 60.94
Extreme 60.94
68.6
1 month 50.59
Extreme 50.59
69.27
Current year 42
Extreme 42
73.3
1 year 17.11
Extreme 17.1062
73.3
3 years 12.21
Extreme 12.21
73.3
5 years 12.21
Extreme 12.21
73.3
10 years 10
Extreme 10
134
Manager TitleAgeSince
Chief Executive Officer 46 2022-03-20
Director of Finance/CFO 42 2026-05-10
Corporate Officer/Principal 35 2021-12-31
Director TitleAgeSince
Director/Board Member 79 2015-06-29
Director/Board Member 63 2015-06-29
Director/Board Member 49 2021-04-07
Date Insider Type Main position Quantity % Market Cap.
06-14Fiscal year

Director

12,060 0.0414%
06-14Fiscal year

Chairman

12,060 0.0414%
06-14Fiscal year

Director

12,060 0.0414%
Change 5-day change 1-year change 3-year change Capi.($)
-2.93%-3.19%+178.68%+223.35% 1.99B
-1.53%-1.43%+71.67%+129.70% 57.72B
-2.45%-7.32%+65.23%+83.15% 52.65B
+3.27%+8.91%+21.21%+471.23% 24.46B
-0.81%+0.52%-15.01%-12.47% 23.84B
-3.05%+3.06%+42.36%-5.66% 19.28B
-0.24%+5.11%+38.76%-25.95% 17.8B
+2.34%+14.18%+220.96%+380.99% 17.29B
-6.73%+9.90%+36.04% - 15.28B
-1.70%+3.98%+28.96%+194.23% 14.35B
Average -1.38%+4.65%+68.89%+159.84% 24.47B
Weighted average by Cap. -1.28%+2.68%+58.78%+140.98%

Financials

2026 *2027 *
Net sales 110M 96.47M 89.07M 82.3M 156M 10.53B 159M 1.07B 416M 5.15B 413M 404M 17.89B 154M 135M 124M 115M 218M 14.71B 222M 1.5B 581M 7.2B 577M 564M 24.99B
Net income -7.47M -6.55M -6.05M -5.59M -10.59M -715M -10.8M -72.69M -28.24M -350M -28.04M -27.43M -1.21B 129M 113M 104M 96.31M 183M 12.32B 186M 1.25B 487M 6.03B 483M 473M 20.94B
Net Debt -92.22M -80.89M -74.68M -69.01M -131M -8.83B -133M -898M -349M -4.32B -346M -339M -15B -293M -257M -237M -219M -416M -28.06B -424M -2.85B -1.11B -13.73B -1.1B -1.08B -47.67B
Logo AnaptysBio, Inc.
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
Employees
104
Date Price Change Volume
26-07-08 US$65.35 -2.93% 1,155,322
26-07-07 US$67.33 +8.05% 947,775
26-07-06 US$62.31 -1.75% 559,584
26-07-02 US$63.42 -3.07% 1,355,586
26-07-01 US$65.43 -3.07% 772,650
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
67.32USD
Average target price
87.09USD
Spread / Average Target
+29.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANAB Stock